ロード中...
Anti-CD22 (90)Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
A lingering criticism of radioimmunotherapy in non-Hodgkin lymphoma is the use of cold anti-CD20 antibody along with the radiolabeled anti-CD20 antibody. We instead combined radioimmunotherapy with immunotherapy targeting different B-cell antigens. We evaluated the anti-CD22 (90)Y-epratuzumab tetrax...
保存先:
| 出版年: | Haematologica |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ferrata Storti Foundation
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4222463/ https://ncbi.nlm.nih.gov/pubmed/25150258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.112110 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|